LDS/Medical Tests/Dopamine transporter (DAT1) (SLC6A3) Genotyping

Dopamine transporter (DAT1) (SLC6A3) Genotyping

The dopamine transporter (DAT) has a central role in dopamine transmission, as it regulates synaptic dopamine levels by mediating dopamine reuptake by presynaptic neurons. DAT is an integral membrane protein that transports the neurotransmitter serotonin from synaptic spaces into presynaptic neurons. DAT is encoded by the SLC6A3/DAT1 gene and genetic variation in the 3' untranslated region impacts the binding of drugs such as methylphenidate and cocaine. The 3' UTR 40-bp variable number of tandem repeats (VNTR) polymorphism gives rise to three to 11 tandem repeats of a 40-bp sequence, with nine or 10 repeats being the most common alleles.

The VNTR has been associated with methylphenidate and serotonin reuptake inhibitor (SSRI) response, with the 9-repeat allele associated with poorer response to SSRIs and the 10-repeat allele associated with poorer response to methylphenidate. In vitro, the 10-repeat allele is associated with a 50% greater transporter density.

In addition, the 10-repeat allele is associated with childhood ADHD, while the 9-repeat allele is associated with persistence of the condition into adulthood, suggesting the variant has a modulating, not a causal role in ADHD.

Variation in the number of repeats is also associated with idiopathic epilepsy, dependence on alcohol and cocaine, susceptibility to Parkinson disease, and protection against nicotine dependence.

  • Screening for treatment-resistant depression and predicting response to serotonin reuptake inhibitor
  • Evaluation of dopamine transporter density; identifying patients with decreased transporter density
  • Identifying candidates for treatment with serotonin reuptake inhibitor therapy
  • Identifying candidates for treatment with methylphenidate
  • ADHD prognosis

The DAT1 VNTR ranges from three to 11 repeats, with 9 and 10 repeats being the most common. The 10-repeat allele yields a 50% greater transporter density than the 9-repeat allele. Genotypes are reported as 10/10 (homozygous 10), 9/10 (heterozygous), and 9/9 (homozygous 9).

  • Patients with the homozygous 10/10 genotype are more likely to exhibit poorer response to methylphenidate and a better response to serotonin reuptake inhibitors
  • Patients with the homozygous 9/9 genotype are more likely to exhibit a better response to methylphenidate and a poorer response to serotonin reuptake inhibitors
  • Presence of the 9-repeat allele is associated with increased risk for Alzheimer’s disease and ADHD. Each copy of the 9-repeat allele is associated with greater disease risk
  • The 10-repeat allele is the most frequent, with an overall frequency of 74%. The 9-repeat allele is the second-most frequent allele (23%).

Genotypes 10/10 (homozygous 10 repeats of the 40-basepair 3-prime VNTR)

Allele Specific Primer Extension (ARMS) by Real-time Polymerase chain reaction (PCR), Next generation sequencing (NGS), Conventional Sequencing.

Whole blood (EDTA), saliva, or buccal swab.

 

Stability

  • Ambient: 5 days
  • Refrigerated: 7 days
Serotonin, dopamine, and catecholamine levels, Catechol-O-methyltransferase Genotyping (COMT), Drug monitoring.
3-7 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login